Skip to main content

Posts tagged with "Why Everyone Loves Us"

  • Clinical Trials

    More on KV and Makena’s Pricing

    I wanted to do some follow-up on the Makena story – the longtime progesterone ester drug that has now been newly FDA-approved and newly made two order of magnitude more expensive. (That earlier post has the details, for those who might not have been following). Steve Usdin at BioCentury has, in the newsletter’s March 21st… Read More
  • Clinical Trials

    Makena’s Price: What to Do?

    The situation with KV Pharmaceuticals and the premature birth therapy Makena has been all over the news in the last couple of days. Briefly, Makena is an injectable progesterone formulation, given to women at risk of delivering prematurely. It went off the market in the early 1990s, because of side effect concerns and worries about… Read More
  • Why Everyone Loves Us

    Public Outreach

    Taking on questions from all comers about the drug industry, here I am over at Reddit’s “Ask Me Anything” section. Have a look if you like – the questions vary greatly, is all I’ll say. . . Read More
  • Clinical Trials

    That $43 Million R&D Figure

    One of the readers in the comments section to the last post noticed Rebecca Warburton trying to clarify that absurd $43-million-per-drug R&D figure. You’ll find her response in the comments section to the Slate piece that brought this whole study so much attention. Says Warburton: . . .Our estimate of $59 million is the median… Read More
  • Business and Markets

    The Costs of Drug Research: Beginning a Rebuttal

    Note: a follow-up post to this one can be found here. I’ve had a deluge of emails asking me about this article from Slate on the costs of drug research. It’s based on this recent publication from Donald Light and Rebecca Warburton in the London School of Economics journal Biosocieties, and it’s well worth discussing. Read More
  • Clinical Trials

    Use Avastin! Don’t Use Avastin!

    The Genentech/Roche drug Avastin has been in the news a lot lately, mostly about cost/benefit analysis for its uses in oncology. It’s nobody’s idea of a cheap drug even for those indications where it shows results. But there’s one therapeutic area where it’s actually the bargain alternative. That’s AMD, wet age-related… Read More
  • Business and Markets

    Ahem: “Sell Gobs of Dope”?

    Thanks to Jim Edwards at Bnet, we have an example of some of the worst pharma sales techniques imaginable. A lawsuit alleging that Gilead Pharmaceuticals had been illegally pushing off-label indications for their angina medication Ranexa (ranolizine) was dropped recently, which brought a lot of court papers into view. According to the whistle-blowe… Read More
  • Why Everyone Loves Us

    Ghostwriting On the Larger Scale

    You’ve heard, no doubt, of the problem of ghostwritten articles associated with the drug industry. But now there’s a report of an entire ghostwritten book. It is (was, since it came out over ten years ago) a guide for family physicians on psychiatric pharmacotherapy, and its authors – scratch that, I mean the names on… Read More
  • Diabetes and Obesity

    Avandia Goes Down: A Research Rant

    So now Avandia (rosiglitazone) looks to be withdrawn from the market in Europe, and heavily restricted here in the US. This isn’t much of a surprise, given all the cardiovascular worries about it in recent years, but hindsight. Oh, hindsight: all that time and effort put into PPAR ligands, back when rosi- and pioglitazone were… Read More
  • Why Everyone Loves Us

    The Life of a Key Opinion Leader

    Here’s an uncomplimentary look at the whole concept of “Key Opinion Leaders” in drug marketing. I think this part gets at the real reason many people agree to do this (and a lot of other things besides): “It strokes your narcissism,” says Erick Turner, a psychiatrist at the Oregon Health and Science University. There i… Read More